Please try another search
For the fiscal year ended 31 December 2021, Plumbline Life Sciences Inc revenues was not reported. Net loss increased 18% to W1.81B. Higher net loss reflects Commission Income decrease of 81% to W69.8M (income), R & D Expense increase of 15% to W871.5M (expense), Loss on Foreign Currency Translation increase from W2.9M to W92.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -W569.20 to -W653.27.
Period Ending: | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 |
Operating Income | -1537.15 | -1604.43 | -3885.7 | -2042.56 |
Net Income | -1814.88 | -1531.64 | -4390.2 | -3207.42 |
Period Ending: | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Assets | 1251.83 | 1650.53 | 1508.86 | 471.69 |
Total Liabilities | 3070.5 | 3054.85 | 7042.93 | 2617.3 |
Total Equity | -1818.67 | -1404.32 | -5534.08 | -2145.61 |
Period Ending: | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Period Length: | 12 Months | 12 Months | 12 Months | 12 Months |
Cash From Operating Activities | -1789.81 | -2092.97 | -1479.03 | -1535.09 |
Cash From Investing Activities | -0.3 | -46.47 | 12.27 | -140.97 |
Cash From Financing Activities | 1399.89 | 2131.75 | 2549.12 | 1844.55 |
Net Change in Cash | -390.22 | -7.69 | 1082.36 | 168.49 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review